nach oben

International Journal of Clinical Oncology

Erschienen in:

04.03.2020 | Original Article

Use of a prognostic risk score that aggregates the FDG-PET/CT SUVmax, tumor size, and histologic group for predicting the prognosis of pStage I lung adenocarcinoma

verfasst von: Naoya Kawakita, Hiroaki Toba, Yukikiyo Kawakami, Hiromitsu Takizawa, Yoshimi Bando, Hideki Otuska, Daisuke Matsumoto, Mika Takashima, Mitsuhiro Tsuboi, Mitsuteru Yoshida, Kazuya Kondo, Akira Tangoku

Erschienen in: International Journal of Clinical Oncology | Ausgabe 6/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

pStage I includes clinicopathologically diverse groups. This study aimed to identify the prognostic factors for pStage I lung adenocarcinoma.

Methods

We retrospectively reviewed 208 patients with pStage I adenocarcinomas who underwent curative resection in our institute between 2006 and 2013. The maximum standardized uptake value (SUVmax) on [F18]-fluoro-deoxy-d-glucose positron emission tomography-computed tomography (PET/CT) was evaluated. Adenocarcinomas were categorized into the following histologic groups: group 0 (minimally invasive adenocarcinoma and lepidic predominant adenocarcinoma), group 1 (papillary predominant adenocarcinoma), and group 2 (acinar predominant adenocarcinoma and all the remaining subtypes). We assessed the relationship between disease-free survival (DFS) and clinicopathological factors.

Results

Multivariate analysis of DFS demonstrated that SUVmax > 3.0 (p < 0.001), total tumor size > 20 mm (p = 0.016), and histologic groups (p < 0.05) were independent prognostic factors. The prognostic risk score (PRS) was calculated using the following equation: PRS = SUVmax (≤ 3.0: 0 point, > 3.0: 2 points) + total tumor size (≤ 20 mm: 0 point, > 20 mm: 1 point) + histologic group (group 0: 0 point, group 1: 1 point, group 2: 2 points). Patients were divided into the following three risk groups: low-risk (PRS 0–2 points, n = 136), intermediate-risk (PRS 3–4 points, n = 49), and high-risk groups (PRS 5 points, n = 13). The 5-year DFS rates were 93.2%, 50.6%, and 30.8% for the low-, intermediate-, and high-risk groups, respectively (p < 0.001).

Conclusions

The PRS aggregating the FDG-PET/CT SUVmax, total tumor size, and histologic group predicts the prognosis of pStage I lung adenocarcinoma.

Nur mit Berechtigung zugänglich

Fu C, Liu Z, Zhu F et al (2016) A meta-analysis: is low-dose computed tomography a superior method for risky lung cancers screening population? Clin Respir J 10:333–341CrossRefPubMed

Sawabata N, Miyaoka E, Asamura H et al (2011) Japanese lung cancer registry study of 11,663 surgical cases in 2004: demographic and prognosis changes over decade. J Thorac Oncol 6:1229–1235CrossRefPubMed

Masuda M, Committee for Scientific Affairs, The Japanese Association for Thoracic Surgery et al (2016) Thoracic and cardiovascular surgery in Japan during 2014: annual report by the Japanese association for thoracic surgery. Gen Thorac Cardiovasc Surg 64:665–697CrossRefPubMedPubMedCentral

Goldstraw P, Crowley J, Chansky K et al (2007) The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2:706–714CrossRefPubMed

Yoshizawa A, Sumiyoshi S, Sonobe M et al (2013) Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients. J Thorac Oncol 8:52–61CrossRefPubMed

Yang HC, Kim HR, Jheon S et al (2015) Recurrence risk-scoring model for stage I adenocarcinoma of the lung. Ann Surg Oncol 22:4089–4097CrossRefPubMed

Uehara H, Tsutani Y, Okumura S et al (2013) Prognostic role of positron emission tomography and high-resolution computed tomography in clinical stage IA lung adenocarcinoma. Ann Thorac Surg 96:1958–1965CrossRefPubMed

Kadota K, Colovos C, Suzuki K et al (2012) FDG-PET SUVmax combined with IASLC/ATS/ERS histologic classification improves the prognostic stratification of patients with stage I lung adenocarcinoma. Ann Surg Oncol 19:3598–3605CrossRefPubMedPubMedCentral

Nair VS, Krupitskaya Y, Gould MK (2009) Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol 4:1473–1479CrossRefPubMed

10.

Sun Y, Hou L, Yang Y et al (2016) Two-gene signature improves the discriminatory power of IASLC/ATS/ERS classification to predict the survival of patients with early-stage lung adenocarcinoma. Oncol Targets Ther 9:4583–4591CrossRef

11.

Yoshizawa A, Motoi N, Riely GJ et al (2011) Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases. Mod Pathol 24:653–664CrossRefPubMed

12.

Takahashi Y, Horio H, Hato T et al (2015) Prognostic significance of preoperative neutrophil-lymphocyte ratios in patients with stage I non-small cell lung cancer after complete resection. Ann Surg Oncol 22(Suppl 3):S1324–1331CrossRefPubMed

13.

Yoshino I, Kawano D, Oba T et al (2006) Smoking status as a prognostic factor in patients with stage I pulmonary adenocarcinoma. Ann Thorac Surg 81:1189–1193CrossRefPubMed

14.

Hamada C, Tanaka F, Ohta M et al (2005) Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer. J Clin Oncol 23:4999–5006CrossRefPubMed

15.

Kato H, Ichinose Y, Ohta M et al (2004) A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350:1713–1721CrossRefPubMed

16.

Toba H, Kondo K, Sadohara Y et al (2013) 18F-fluorodeoxyglucose positron emission tomography/computed tomography and the relationship between fluorodeoxyglucose uptake and the expression of hypoxia-inducible factor-1alpha, glucose transporter-1 and vascular endothelial growth factor in thymic epithelial tumours. Eur J Cardiothorac Surg 44:e105–112CrossRefPubMed

17.

Travis WD, Brambilla E, Noguchi M et al (2011) International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6:244–285CrossRefPubMedPubMedCentral

18.

Nakamura H, Saji H, Shinmyo T et al (2015) Close association of IASLC/ATS/ERS lung adenocarcinoma subtypes with glucose-uptake in positron emission tomography. Lung Cancer 87:28–33CrossRefPubMed

19.

Russell PA, Wainer Z, Wright GM et al (2011) Does lung adenocarcinoma subtype predict patient survival?: a clinicopathologic study based on the new international association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 6:1496–1504CrossRefPubMed

20.

Watanabe K, Nomori H, Ohtsuka T et al (2006) [f-18]fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol 36:403–409CrossRefPubMed

21.

Paesmans M, Berghmans T, Dusart M et al (2010) Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: Update of a systematic review and meta-analysis by the European lung cancer working party for the international association for the study of lung cancer staging project. J Thorac Oncol 5:612–619CrossRefPubMed

22.

Gu J, Lu C, Guo J et al (2013) Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-a single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol 107:474–480CrossRefPubMed

23.

Warth A, Muley T, Meister M et al (2012) The novel histologic international association for the study of lung cancer/American thoracic society/European respiratory society classification system of lung adenocarcinoma is a stage-independent predictor of survival. J Clin Oncol 30:1438–1446CrossRefPubMed

24.

Tsuta K, Kawago M, Inoue E et al (2013) The utility of the proposed IASLC/ATS/ERS lung adenocarcinoma subtypes for disease prognosis and correlation of driver gene alterations. Lung Cancer 81:371–376CrossRefPubMed

25.

Kadota K, Yeh YC, Sima CS et al (2014) The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. Mod Pathol 27:690–700CrossRefPubMed

26.

Nakazato Y, Maeshima AM, Ishikawa Y et al (2013) Interobserver agreement in the nuclear grading of primary pulmonary adenocarcinoma. J Thorac Oncol 8:736–743CrossRefPubMed

27.

Takamochi K, Oh S, Matsunaga T et al (2017) Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma. J Thorac Cardiovasc Surg 154(1768–1774):e1761

28.

Lin CY, Wu YM, Hsieh MH et al (2017) Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma. PLoS ONE 12:e0186567CrossRefPubMedPubMedCentral

29.

Hung JJ, Yeh YC, Jeng WJ et al (2014) Predictive value of the international association for the study of lung cancer/American thoracic society/European respiratory society classification of lung adenocarcinoma in tumor recurrence and patient survival. J Clin Oncol 32:2357–2364CrossRefPubMed

30.

Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura G (2014) The correlation of the international association for the study of lung cancer (IASLC)/American thoracic society (ATS)/European respiratory society (ERS) classification with prognosis and EGFR mutation in lung adenocarcinoma. Ann Thorac Surg 98:453–458CrossRefPubMed

31.

Xu CH, Wang W, Wei Y et al (2015) Prognostic value of the new international association for the study of lung cancer/American thoracic society/European respiratory society classification in stage IB lung adenocarcinoma. Eur J Surg Oncol 41:1430–1436CrossRefPubMed

32.

Arriagada R, Auperin A, NSCLC Meta-analyses Collaborative Group et al (2010) Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: Two meta-analyses of individual patient data. Lancet 375:1267–1277CrossRefPubMed

33.

Pignon JP, Tribodet H, Scagliotti GV et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the lace collaborative group. J Clin Oncol 26:3552–3559CrossRefPubMed

34.

Douillard JY, Rosell R, De Lena M et al (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7:719–727CrossRefPubMed

35.

Winton T, Livingston R, Johnson D et al (2005) Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589–2597CrossRefPubMed

36.

Arriagada R, Bergman B, Dunant A et al (2004) Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350:351–360CrossRefPubMed

37.

Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT (2017) The eighth edition lung cancer stage classification. Chest 151:193–203CrossRefPubMed

Titel: Use of a prognostic risk score that aggregates the FDG-PET/CT SUVmax, tumor size, and histologic group for predicting the prognosis of pStage I lung adenocarcinoma
verfasst von: Naoya Kawakita
Hiroaki Toba
Yukikiyo Kawakami
Hiromitsu Takizawa
Yoshimi Bando
Hideki Otuska
Daisuke Matsumoto
Mika Takashima
Mitsuhiro Tsuboi
Mitsuteru Yoshida
Kazuya Kondo
Akira Tangoku
Publikationsdatum: 04.03.2020
Verlag: Springer Singapore
Erschienen in: International Journal of Clinical Oncology / Ausgabe 6/2020
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-020-01637-6

Springer Medizin

Use of a prognostic risk score that aggregates the FDG-PET/CT SUVmax, tumor size, and histologic group for predicting the prognosis of pStage I lung adenocarcinoma